Objective: Cholinergic vasodilation has been thought to play little if any role in the regulation of blood pressure in humans. Autonomic denervation potentiates the vasoconstriction evoked by nitric oxide synthase inhibition in humans, but the mechanism is unclear. We hypothesized that this may be related to loss of neuronal, non-nitric-oxide-dependent vasodilation. Methods: To test this hypothesis, we examined effects of cholinergic blockade on blood pressure, heart rate and peripheral vascular responses to systemic infusion of the nitric-oxide-dependent vasoconstrictor L-NMMA (0.5 mg / kg / min over 15 min) in eight normal subjects. Results: The L-NMMA-induced increase in mean (6S.E.) arterial pressure was roughly three times larger (P50.002) in the presence than in the absence of cholinergic blockade (3866 vs. 1362 mmHg). Similarly, the increase in systemic and calf vascular resistance was more than twofold larger during L-NMMA-atropine. This potentiation was specific for nitric-oxide-dependent vasoconstriction, because atropine did not alter the responses to phenylephrine infusion. Cholinergic blockade also altered (P50.004) the heart rate response to nitric oxide synthase inhibition; during L-NMMA alone heart rate decreased by 1062 beats / min, whereas during L-NMMA-atropine infusion it increased by 1464 beats / min. Conclusion: Cholinergic mechanisms play an important hitherto unrecognized role in offsetting the hypertension and cardiac sympathetic activation caused by nitric oxide synthase inhibition in humans. Decreased parasympathetic activity and impaired nitric oxide synthesis characterize several cardiovascular disease states, as well as normal aging. The conjunction of these two defects could trigger sudden death and contribute to the hypertension of the elderly.
Introduction
L-arginine by the ubiquitous enzyme nitric oxide synthase (NOS) [6] , regulates vascular tone by a direct action at the The vascular endothelium and the autonomic nervous vasculature [7] , by modulating central neural vasoconstricsystem interact between each other and play a key role in tor outflow [7] [8] [9] [10] [11] [12] [13] , and via its release from sympathetic the regulation of the cardiovascular system [1, 2] . Major nitrergic vasodilator nerves [14] . While the importance of cardiovascular disease states such as hypertension, heart parasympathetic control of heart rate (HR) is well estabfailure and myocardial infarction are associated with lished [15] , little is known regarding the role of cholinergic endothelial [3, 4] and autonomic dysfunction [5] , as is vasodilator mechanisms in the regulation of blood pressure aging, another risk factor for cardiovascular disease. Nitric in humans [16] , and the possibility of an interaction oxide (NO) which is synthesized from the amino acid between the cholinergic and the NO-L-arginine system. Autonomic denervation potentiates the vasoconstrictor nism is not known [17] . We hypothesized that cholinergic mg / kg / min for 15 min), D-arginine (100 mg / kg over 10 this study after providing informed written consent. All min, n55) and L-arginine (100 mg / kg over 10 min). subjects were normotensive, were taking no medications, Hemodynamic measurements were recorded during two and had no evidence of metabolic or cardiovascular 5-min periods of the saline infusion and during the last 5 disease. The studies were performed in the morning after min of each drug infusion. In four of the subjects we also an overnight fast. The subjects were asked to abstain from measured cardiac output (echocardiography). The present alcohol, caffeine and tobacco for at least 24 h before each dose of L-NMMA was chosen, because it was found to study. The experimental protocol was approved by the consistently increase calf vascular resistance [9] . L-ArInstitutional Review Board on Human Investigation and ginine at the dose used in these studies was found to the investigation conforms with the principles outlined in consistently reverse the hemodynamic effect of L-NMMA the Declaration of Helsinki.
[9].
General procedures 2.6.2. Protocol 2: cardiovascular effects of L-NMMA infusion during cholinergic blockade
The subjects were studied in the supine position. Heart
After instrumentation the subject rested quietly for 30 rate (electrocardiogram) and blood pressure (Finapres) min. After resting control values had been measured, a were measured continuously. For drug infusion, an in- 2 2 prime (0.4 mg / m over 10 min) continuous (0.3 mg / m / travenous catheter was inserted in an antecubital vein. h) atropine infusion was started. 30 min after its start, sequential infusions of L-NMMA (0.5 mg / kg / min for 15 2.3. Measurement of calf blood flow min), D-arginine (100 mg / kg over 10 min, n55) and L-arginine (100 mg / kg over 10 min) were superimposed Calf blood flow was measured by venous occlusion on the atropine infusion. Hemodynamic measurements plethysmography, using mercury-in-Silastic strain gauges.
were recorded during two 5-min periods of baseline and The calf was elevated 10-15 cm above the level of the atropine infusion, and during the last 5 min of the Lright atrium to collapse the veins. The circulation to the NMMA infusion. The present dose of atropine was chosen, foot was arrested by inflating a cuff around the ankle because we had previously found that it abolished the during blood flow determinations, which were performed vasodilator response to intra-arterial acetylcholine infusion at 15-s intervals over a 5-min period [18] .
[20]. The aim of this protocol was to test whether the tract was multiplied by the velocity time integral of the potentiation of the vasoconstriction by cholinergic blocksystolic flow to obtain the stroke volume. The cardiac ade was specific for the NO-dependent vasoconstrictor output was then calculated by multiplying the stroke L-NMMA or not. To this end we examined the effects of volume by the HR. The diameter of the left ventricular cholinergic blockade on the vasoconstrictor response outflow tract was determined in a parasternal long axis evoked by the non-NO-dependent vasoconstrictor view and the systolic flow by a pulse Doppler sample from phenylephrine. Five of the subjects returned for this an apical 5 chamber view.
protocol. The timing of the phenylephrine infusions was identical to that of the L-NMMA infusions in protocols 1 and 2. In a first session, after 30 min of normal saline infusion (1 ml / min), they received a 15-min phenylephrine infusion titrated at a dose to match the increase in arterial pressure observed during the L-NMMA infusion. Hemodynamic measurements were recorded during two 5-min periods of the saline infusion and during the last 5 min of the phenylephrine infusion.
In a second session, on a separate day, the same dose of phenylephrine was superimposed on an atropine infusion at the same dose as that used in protocol 2. Hemodynamic measurements were recorded during two 5-min periods of baseline and atropine infusion, and during the last 5 min of the phenylephrine-atropine infusion.
Protocol 4: hemodynamic effects of L-NMMA and atropine during concomitant propranolol infusion
Since we found that in protocol 2 HR increased during the L-NMMA infusion, the aim of this protocol was to test whether this effect was caused by b-adrenergic stimulation. Four of the subjects returned for this study. The protocol was identical to protocol 2, except that together with atropine, propranolol was co-infused as a prime (0.1 mg / kg over 10 min) continuous (0.01 mg / kg / min) infusion. This dose of propranolol abolishes isoproteronolinduced hemodynamic and chronotropic responses [20] . Systemic vascular resistance was calculated as mean arterial pressure divided by the cardiac output and ex-5 pressed in dynes s per cm . The measurements of calf blood flow, arterial pressure and HR that were collected arterial pressure was roughly three times larger in the over 5-min periods were averaged to a single value.
presence NMMA alone and L-NMMA-atropine). The L-NMMAinduced hemodynamic effects plateaued after the 10th Cholinergic blockade markedly potentiated the Lminute of infusion (data not shown) and were related to NMMA induced pressor and vasoconstrictor effects (Fig. NO inhibition, because they were reversed by L-arginine 1, Table 1 ). The L-NMMA-induced increase in mean (but not D-arginine, data not shown) infusion (Table 1) . phenylephrine infusion . We found that cholinergic blockade had a dramatic ropine prevented the phenylephrine-induced decrease in effect on the pressor response to NOS inhibition in these HR; HR decreased during phenylephrine alone, whereas it healthy subjects, since the L-NMMA-induced increase in remained unchanged during phenylephrine-atropine infumean arterial pressure was roughly three times larger in the sion (Table 2) .
presence than in the absence of atropine infusion. Our data indicate that cholinergic vasodilation is much more im-3.3. Effects of propranolol on HR responses to portant than previously thought, and offsets roughly two concomitant L-NMMA-atropine infusion thirds of the pressor effect caused by NOS inhibition. The potentiation of the pressor effect by cholinergic blockade Propranolol did not alter the pressor response to Lwas specific for NO-dependent vasoconstriction (as evi-NMMA-atropine infusion (mean arterial pressure indenced by the phenylephrine studies). Moreover, the Lcreased by 2969 and 32614 mmHg in the presence and NMMA-induced hemodynamic effects were related speabsence of propranolol, respectively), but abolished the cifically to inhibition of NO synthesis, since they were L-NMMA-induced increase HR; when L-NMMA was reversed by L-arginine (but not D-arginine) infusion. Autoinfused during atropine alone, it increased the HR from nomic denervation potentiates the vasoconstrictor effect of 9365 to 10369 beats / min (P,0.05), whereas when it was NOS inhibition in humans, but it is not clear whether this infused during atropine-propranolol, HR remained unobservation is related to augmented contribution of NO to changed at 8365 and 8266 beats / min, respectively (P5 local vascular resistance regulation after denervation or to We are indebted to Dr. Reza Owlya for performing the echocardiographic measurements. mechanisms [17] . The present findings could be consistent with the hypothesis that this augmented vasoconstriction was related, at least in part, to the latter mechanism.
